Windlas Biotech IPO Review
Windlas Biotech IPO is yet to receive analyst coverage — analyst reports and verdicts will be updated here as and when they are published. The IPO is priced in the band of ₹448-460 per share with a minimum lot size of 30 shares (minimum investment of ₹13,800). Subscription ran from 04 Aug 2021 to 06 Aug 2021. The issue size is ₹402 crore, a mix of fresh issue and offer for sale. In the meantime, you can track the live GMP and subscription status for early market signals.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Detailed review
Download our Android App to check other reviews.
Latest IPO reviews
How analysts rated the most recent mainboard issues — and, where they have listed, how the call played out.
Frequently asked
Should I apply for Windlas Biotech IPO?
Analyst coverage for Windlas Biotech IPO has not been published yet. Verdicts will be added here as analyst reports come in. IPO Guru does not make buy or sell recommendations. Read the individual analyst reports and consult a SEBI-registered advisor before investing.
What does the score of N/A mean for Windlas Biotech IPO?
Analyst scoring is not yet available for Windlas Biotech IPO. The score will be updated once analyst reports start coming in.
What was the actual listing price of Windlas Biotech IPO?
Windlas Biotech IPO listed on August 16, 2021 at ₹437, against the issue price of ₹460 — a loss of -5% (₹23 per share). View the full GMP history page for day-wise pre-listing trends.
What is the price band and lot size of Windlas Biotech IPO?
Windlas Biotech IPO was priced at ₹448-460 per share. The minimum lot size is 30 shares, making the minimum investment approximately ₹13,800 at the upper end of the price band. Subscription ran from 04 Aug 2021 to 06 Aug 2021.
Explore Windlas Biotech IPO further
Analyst views are one input. Read them alongside the demand, the grey market and the filings before you decide.
It has listed — go back to the fundamentals.
Live grey market premium, Kostak and Subject to Sauda, with the day-wise trend.
Category-wise demand from QIB, NII and retail investors, updated through the day.
Check with your PAN whether shares were credited to your demat account.
A verdict is an opinion, not a guarantee.
IPO Guru collects analyst views, GMP, subscription and allotment for every Mainboard and SME issue. Weigh them together — and against the offer document — before you apply.
Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.
